For how we live.
A draft replacing a 2003 document would extend hepatic-impairment dosing studies to biologic drugs and to drug effects, not just blood levels. It is open for comment before the agency finalises it.
At recommended doses it is one of the best-tolerated painkillers. The liver harm concentrates at high doses, and half of the failure cases are unintentional, often from combining products.
Two meta-analyses tie an extra two cups a day to roughly a third lower risk of both liver cancer and cirrhosis, with decaf showing a smaller effect. It is all observational, and the evidence quality is graded very low.
Hepatitis C is usually silent for years and is the reason for much chronic liver disease. A short course of antiviral pills cures more than 95% of cases, which is what changed the screening advice.
Bodybuilding steroids, green tea extract and multi-ingredient blends are the products most often implicated. A liver injury from a supplement often can't be traced to a single named ingredient.
A Cochrane review of 18 trials and an NIH-funded randomised trial both failed to show that milk thistle improves liver disease. Product quality is also inconsistent, with some pills contaminated or mislabelled.
No randomised controlled trial has tested a commercial detox diet in people, and the reviews that exist find no compelling evidence they remove toxins or aid weight. Some carry real risks.
MASLD is excess fat in the liver unrelated to alcohol, and about 30% of adults have it. The best-evidenced way to reverse the inflamed form is weight loss — and how much you lose tracks how much the liver recovers.
Raised liver enzymes are common and mean the liver may be under strain, not that a disease is confirmed. The pattern, degree and duration of the change are what a clinician reads, not a single flag.
The two dominant causes of chronic liver disease are alcohol and metabolic fat. For alcohol, cirrhosis risk climbs exponentially with intake — and in women it was already raised at about one drink a day.
SYNCHRONIZE-MASLD reports 84.2% of survodutide patients hitting a 30% cut in liver fat at 48 weeks. The trial measured fat on MRI, not fibrosis on biopsy — which is where the harder question still sits.
Brown University researchers pooled 16 studies covering more than 150,000 people. The consistent finding is not detox — it is that most participants are still drinking less months later.
Dapagliflozin beat placebo on liver histology over 48 weeks in six Chinese hospitals. Weeks later, European regulators recommended the first purpose-built drug for the same disease.